Liquid Stable Kit Determines Homocysteine in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Jun 2012 |
A liquid stable homocysteine kit provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is an indicator of a number of disease markers and should be an integral part of a laboratory’s testing menu.
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Latest Clinical Chem. News
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Channels
Molecular Diagnostics
view channel
Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read moreRoutine Genetic Marker May Help Guide Targeted Therapy in Acute Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer with widely variable treatment outcomes between patients. Choosing which individuals will benefit from targeted agents remains difficult, limiting... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read more
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more







